LSTA vs. KFFB, LUMO, ORGS, OTRK, NEOS, ASRT, TLSA, CNTB, ETON, and ORMP
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Kentucky First Federal Bancorp (KFFB), Lumos Pharma (LUMO), Orgenesis (ORGS), Ontrak (OTRK), Neos Therapeutics (NEOS), Assertio (ASRT), Tiziana Life Sciences (TLSA), Connect Biopharma (CNTB), Eton Pharmaceuticals (ETON), and Oramed Pharmaceuticals (ORMP).
Kentucky First Federal Bancorp (NASDAQ:KFFB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
3.2% of Kentucky First Federal Bancorp shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 5.3% of Kentucky First Federal Bancorp shares are owned by insiders. Comparatively, 21.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Lisata Therapeutics has a net margin of 0.00% compared to Lisata Therapeutics' net margin of -3.85%. Lisata Therapeutics' return on equity of -1.21% beat Kentucky First Federal Bancorp's return on equity.
Kentucky First Federal Bancorp received 77 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Lisata Therapeutics an outperform vote while only 60.00% of users gave Kentucky First Federal Bancorp an outperform vote.
Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 410.20%. Given Kentucky First Federal Bancorp's higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Kentucky First Federal Bancorp.
Kentucky First Federal Bancorp has higher revenue and earnings than Lisata Therapeutics. Kentucky First Federal Bancorp is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Kentucky First Federal Bancorp has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.
In the previous week, Kentucky First Federal Bancorp had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 4 mentions for Kentucky First Federal Bancorp and 3 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.91 beat Kentucky First Federal Bancorp's score of 0.29 indicating that Kentucky First Federal Bancorp is being referred to more favorably in the media.
Summary
Kentucky First Federal Bancorp and Lisata Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
